FDA Priority Review for Roche Enspryng MOGAD
Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 10, 2026
The FDA Priority Review shortens the expected approval timeline for Enspryng in MOGAD, a first-in-class opportunity in a rare disease with no approved therapies, which modestly strengthens Roche's neurology franchise outlook and could add incremental revenue from 2027. The positive regulatory news is likely to be received favorably by investors, though the near-term stock impact is limited given Enspryng's existing approvals and the small MOGAD patient population.
Roche announced on 10 September 2026 that the United States — Food and Drug Administration has granted Priority Review to a supplemental Biologics License Application for Enspryng (satralizumab) for the treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a rare autoimmune disease of the central nervous system with no currently approved treatments. If approved, Enspryng would become the first and only disease-modifying therapy for MOGAD. The filing acceptance is based on positive results from the Phase III METEOROID study, which showed Enspryng reduced the risk of a new relapse by 68% compared to placebo, with 87% of Enspryng-treated patients remaining relapse-free at 48 weeks versus 67% in the placebo arm. The study was presented at the American Academy of Neurology Annual Meeting in April 2026. The FDA is expected to make an approval decision by 10 January 2027. This marks the second FDA Priority Review for Enspryng, following one granted for thyroid eye disease in June 2026. Separately, the European Union — European Medicines Agency has validated the application for Enspryng for MOGAD in Europe, with a International — European Commission decision expected in the third quarter of 2027. Enspryng was developed by Roche Holding — Chugai, a member of the Roche Group, and is marketed in the United States through F. Hoffmann-La Roche — Genentech. Levi Garraway, Roche's Chief Medical Officer, commented on the potential of Enspryng to transform care for MOGAD patients. Roche is headquartered in Switzerland and operates globally, including in the United States.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard